Antifungal chemotherapy.

Abstract

When the decision to treat a fungal infection is made, there are several antifungal agents available for use. AmB remains the first-line drug in the treatment of most systemic fungal infections. Miconazole should be used to treat patients who cannot tolerate AmB or who are infected with AmB-resistant organisms. Ketoconazole has a distinct advantage in that it is a relatively nontoxic oral agent and may prove very effective in treating non-life-threatening chronic fungal infections. Clinical experience with miconazole and ketoconazole is too limited at present to recommend them as first-line therapeutic agents, except in a limited number of clinical situations. 5-FC should only be used in combination with AmB to treat yeast infections.

• Authors: M H Koldin, G Medoff
• Journal: Pediatric clinics of North America (Pediatr Clin North Am) Vol. 30 Issue 1 Pg. 49-61 (Feb 1983) ISSN: 0031-3955 [Print] United States
• PMID: 6338469 (Publication Type: Journal Article, Review)

Chemical References

• Antifungal Agents
• Drug Combinations
• Imidazoles
• Potassium Iodide
• Amphotericin B
• Flucytosine

Topics

• Amphotericin B (adverse effects, metabolism, therapeutic use)
• Antifungal Agents (adverse effects, metabolism, therapeutic use)
• Child
• Child, Preschool
• Drug Combinations
• Flucytosine (adverse effects, metabolism, therapeutic use)
• Humans
• Imidazoles (metabolism, therapeutic use)
• Infant
• Mycoses (drug therapy)
• Potassium Iodide (administration & dosage, therapeutic use)
• Structure-Activity Relationship